US FDA Urged To Stop Slowing Approvals By Seeking Metals Data From Suppliers
Executive Summary
Excipient suppliers complain about agency requests for elemental impurities data that go beyond ICH and USP requirements and delay approvals.
You may also be interested in...
Regulators Find Room For ICH Q3D Metal Impurity Risk Assessments To Improve
The pharmaceutical industry is doing a better job of conducting the risk assessments called for in the ICH Q3D elemental impurity limits guideline, and regulators are not rejecting applications because of poor quality assessments, yet regulators say there is still room for improvement.
IPEC Wants FDA To Clear Up Elemental Impurity Confusion
IPEC-Americas has proposed that FDA issue supplemental question-and-answer guidance to clear up confusion on what elemental impurity information FDA reviewers can ask of manufacturers and their excipient suppliers in connection with pending applications. The group said that generic manufacturers, primarily in India, “continue to have a significant number of questions and misunderstandings” of what elemental impurity information they are supposed to report to FDA.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”